---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-115489"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:38:25.693737+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q1 2025 net loss $46.9M; pipeline progress in obesity, AATD, DMD, HD

## Summary
- Net loss of $46.9M vs $31.6M prior year; revenue $9.2M (down from $12.5M). Cash $243.1M, runway into 2027.
- Obesity: dosing complete in first two INLIGHT cohorts for WVE-007; clinical data expected 2H 2025.
- AATD: RestorAATion-2 dosing at 200 mg Q2W and 400 mg single dose; data on multiple cohorts due 3Q and fall 2025.
- DMD: Positive 48-week FORWARD-53 data with 3.8 sec improvement in TTR vs natural history; NDA submission planned 2026.
- HD: IND submission expected 2H 2025 for potentially registrational Phase 2/3 study of WVE-003.

## SEC filing metadata
- accession: 0001193125-25-115489
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525115489/0001193125-25-115489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525115489/d892783d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-115489
- JSON: https://secwatch.observer/filing/0001193125-25-115489.json
- Plain text: https://secwatch.observer/filing/0001193125-25-115489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.